Murakami Akiko, Ohashi Rina, Minakata Kunihiko, Koyama Ryo, Muraki Keiko, Shukuya Takehito, Namba Yukiko, Ko Ryo, Yagishita Shigehiro, Katsura Yoko, Takahashi Fumiyuki, Sakuraba Shoko, Takahashi Kazuhisa
Dept. of Respiratory Medicine, Juntendo University, Faculty of Medicine.
Gan To Kagaku Ryoho. 2012 Sep;39(9):1357-61.
We retrospectively evaluated the survival benefit of dispensing erlotinib after gefitinib administration in patients with nonsmall cell lung cancer. Ninety patients treated with erlotinib in our hospital were divided into two groups: G+ group patients who were treated with erlotinib with prior gefitinib administration, and G- group patients who were treated with erlotinib without prior gefitinib administration. Median survival time (MST) in all 90 patients was 275 days. MST of 22 patients in the G+ group was shorter than that of 68 patients in G- group, but this difference was not statistically significant (283 days vs 177 days, p=0. 329). MST in 19 patients of the G+group who were administered erlotinib for over 1 month was shorter than that of 49G-group patients who were administered erlotinib over 1 month. However, this difference was also not statistically significant(395 days vs 238 days, p=0. 575). Univariate analysis demonstrated that EGFR mutation unknown, time to progression (TTP) with gefitinib longer than 1 year, gefitnib administration longer than 1 year, and responder to gefitinib, suggest a better prognosis. Mutivariate analysis revealed that only TTP with gefitinib longer than 1 year was an independent prognostic factor for patients in the G+ group.
我们回顾性评估了在非小细胞肺癌患者中吉非替尼给药后再给予厄洛替尼的生存获益情况。我院接受厄洛替尼治疗的90例患者被分为两组：G+组为先前接受过吉非替尼治疗后再接受厄洛替尼治疗的患者，G-组为未接受过吉非替尼治疗而直接接受厄洛替尼治疗的患者。90例患者的中位生存时间（MST）为275天。G+组22例患者的MST短于G-组68例患者，但差异无统计学意义（283天对177天，p = 0.329）。G+组中接受厄洛替尼治疗超过1个月的19例患者的MST短于G-组中接受厄洛替尼治疗超过1个月的49例患者。然而，该差异同样无统计学意义（395天对238天，p = 0.575）。单因素分析表明，表皮生长因子受体（EGFR）突变情况未知、吉非替尼治疗的疾病进展时间（TTP）超过1年、吉非替尼给药时间超过1年以及对吉非替尼有反应者，提示预后较好。多因素分析显示，仅吉非替尼治疗的TTP超过1年是G+组患者的独立预后因素。
